Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes

Joseph R. Testa, PhD, David Malkin, MD, and Joshua D. Schiffman, MD

OVERVIEW

An understanding of the genetic causes and molecular pathways of hereditary cancer syndromes has historically informed our knowledge and treatment of all types of cancers. For this review, we focus on three rare syndromes and their associated genetic mutations including BAP1, TP53, and SDHx (SDHA, SDHB, SDHC, SDHD, SDHAF2). BAP1 encodes an enzyme that catalyzes the removal of ubiquitin from protein substrates, and germline mutations of BAP1 cause a novel cancer syndrome characterized by high incidence of benign atypical melanocytic tumors, uveal melanomas, cutaneous melanomas, malignant mesotheliomas, and potentially other cancers. TP53 mutations cause Li-Fraumeni syndrome (LFS), a highly penetrant cancer syndrome associated with multiple tumors including but not limited to sarcomas, breast cancers, brain tumors, and adrenocortical carcinomas. Genomic modifiers for tumor risk and genotype-phenotype correlations in LFS are beginning to be identified. SDH is a mitochondrial enzyme complex involved in the tricarboxylic acid (TCA) cycle, and germline SDHx mutations lead to increased succinate with subsequent paragangliomas, pheochromocytomas, renal cell carcinomas (RCCs), gastrointestinal stromal tumors (GISTs), and other rarer cancers. In all of these syndromes, the molecular pathways have informed our understanding of tumor risk and successful early tumor surveillance and screening programs.

Hereditary cancer syndromes may account for up to 5% to 10% of new-onset adult cancers. In children, the hereditary cancer syndromes may explain at least 29% of cancer diagnoses. Historically, these syndromes have informed our knowledge and treatment of patients with both familial cancer risk and spontaneous, or de novo, cancer. Herein we describe the molecular pathways and recent advances in three rare hereditary cancer syndromes affecting both children and adults. The clinical translation of this information to effective screening and prevention programs is also discussed.

BAP1 CANCER SYNDROME: PREDISPOSITION TO MESOTHELIOMA AND MELANOCYTIC TUMORS

Recently, there has been an upsurge of interest in BAP1 (BRCA1-associated protein-1), an ubiquitin carboxy-terminal hydrolase (UCH) first described by Rauscher and colleagues. The BAP1 gene was found to be homozygously deleted in two lung carcinoma cell lines; this and other biochemical studies provided the first evidence implicating BAP1 as a tumor suppressor gene. Nearly 15 years later, Harbor and colleagues reported a high frequency of BAP1 mutations in metastasizing uveal melanoma (UM), including one that was germline in origin. Subsequently, two groups simultaneously reported germline mutations in four different high-risk cancer families, suggesting a BAP1-related cancer susceptibility syndrome. In one report, germline inactivating mutations of BAP1 were discovered in two families with high incidence of malignant mesothelioma (MM), UM, and other cancers. In the second report, two families were described in which germline mutations in BAP1 predisposed to multiple melanocytic tumors ranging from epithelioid nevi to atypical melanocytic tumors, with some mutation carriers developing UM or cutaneous melanoma (CM). Below, we focus on the involvement of BAP1 mutations in a new cancer predisposition disorder, now known as the BAP1 cancer syndrome. Notably, however, somatic BAP1 mutations have also been reported in various sporadic tumors including MM, RCC, and a rare, distinct subset of melanocytic tumors known as atypical Spitz tumors (ASTs).

Mesotheliomas are aggressive tumors causally linked to exposure to asbestos or related carcinogenic fibers such as erionite. Although only a small percentage of asbestos-exposed individuals develop MM, clustering of MM occurs in some families, consistent with the idea that genetic factors play a role in its development. Historically, the understanding of MM pathogenesis was understood in the context of somatic genetic losses within chromosome arms 3p, 9p, and 22q, the latter two specifically affecting CDKN2A and NF2, suggesting a multistep cascade involving the inactivation of multiple tumor suppressors. The field was revolutionized recently by the...
Bott and colleagues reported inactivating mutations in \textit{BAP1}, a tumor suppressor gene located at 3p21.1, in 22% of sporadic MMs.\cite{Bott}\textsuperscript{4} Independently, Testa and colleagues similarly discovered somatic mutations of \textit{BAP1} in 22% of sporadic MMs.\cite{Testa}\textsuperscript{5} Moreover, heterozygous \textit{germline} mutations of \textit{BAP1} were identified in two high-risk cancer families in which the predominant malignancy was MM; notably, one family also had two cases of UM,\cite{Bott}\textsuperscript{6} a tumor type previously shown to be associated with somatic \textit{BAP1} mutations.\cite{Testa}\textsuperscript{6} In some cases, tumor tissue was also available, which showed biallelic inactivation of \textit{BAP1}. From the perspective of environmental exposure, it is noteworthy that members of neither of these MM families had been exposed occupationally to asbestos. Moreover, only traces of asbestos were found in their homes, raising the question of whether a genetic factor alone is sufficient for MM development in these families. In one family, a germline splice acceptor site mutation in \textit{BAP1} was identified in all six family members who developed MM as well as in several others who developed variable carcinomas, including one RCC. The mutation resulted in an aberrant splice product and a frameshift predicted to lead to a premature stop codon. In the second family, the germline \textit{BAP1} mutation (a C/G to T/A transition in exon 16 creating a stop codon and premature truncation of the BAP1 protein) was associated with development of various cancers, including seven MMs and two UMs (one occurring in an individual who later developed MM). Intriguingly, germline \textit{BAP1} mutations were also found in 2 of 26 sporadic MMs tested, and both patients with mutant \textit{BAP1} were previously diagnosed with UM.

Concurrent work by Wiesner and colleagues revealed inactivating germline \textit{BAP1} mutations in two families with multiple benign melanocytic tumors;\cite{Wiesner} some affected individuals developed UM or CM,\cite{Testa}\textsuperscript{7} and one family member was subsequently diagnosed with MM.\cite{Wiesner}\textsuperscript{10} The existence of a BAP1-related melanocytic disorder was confirmed by a report of germline \textit{BAP1} inactivation in families with metastatic UM or with both UM and CM; and some carriers also had atypical melanocytic tumors.\cite{Wiesner}\textsuperscript{11} Another group reported a germline \textit{BAP1} mutation in a family with a wide variety of cancers, including three MMs, three UMs, and three CMs.\cite{Bott}\textsuperscript{12} More recently, a germline \textit{BAP1} mutation was identified in a family in which MM was found in four members, none with a history of asbestos exposure; one member also had multiple melanocytic tumors.\cite{Wiesner}\textsuperscript{13} Another recent study uncovered three cases of UM in a family with no aggregation of other cancer diagnoses.\cite{Testa}\textsuperscript{13} The full tumor spectrum associated with germline \textit{BAP1} mutations has yet to be established, as suggested by recent report of a germline \textit{BAP1} splice mutation and truncating frameshift in a family with UM, CM, suspected MM, as well as paraganglioma.\cite{Bott}\textsuperscript{14} Somatic loss of the wild-type BAP1 allele was documented in the paraganglioma, potentially extending the cancer predisposition spectrum.

Ucral tumors known as UMs arise from melanocytes residing within the uvea. Familial UM is rare, comprising fewer than 1% of all UM patients.\cite{Fraumeni}\textsuperscript{15} Unlike MM, the question of whether a specific environmental carcinogen plays an etiologic role is unresolved. In contrast to CM, epidemiologic evidence regarding a potential association between sunlight/UV exposure and UM is considered weak and contradictory.\cite{Fraumeni}\textsuperscript{15} UM is characterized by a strong proclivity for lethal metastasis to the liver.\cite{Bott}\textsuperscript{5} UMs are separated into class 1 tumors, which have low metastatic potential, and class 2 tumors, which exhibit high metastatic risk. Harbour and colleagues used exome capture coupled with next-generation sequencing to search for metastasis-related mutations in highly metastatic UMs.\cite{Harbour} Inactivating somatic mutations of \textit{BAP1} were identified in 26/31 (84%) metastasizing tumors, including one that was germline in origin.

Collectively, these findings suggest a BAP1 cancer syndrome in which affected families are predisposed to MM, UM, atypical melanocytic tumors, CM, and possibly other cancers. The germline mutations observed in these families are spread throughout the \textit{BAP1} coding region, spanning all of the known functional and protein-protein interaction domains (Fig. 1). All mutations result in predicted loss of the nuclear localization signal, thereby abolishing BAP1 function in the nucleus. Biallelic inactivation of \textit{BAP1} has been documented in multiple tumors from these high-risk families, strongly suggesting that \textit{BAP1} acts as a classical tumor suppressor gene.
BAP1 Function

BAP1 is one of four UCH members involved in the rescue of poly-ubiquitinated substrates from proteasomal degradation. BAP1 is the sole nuclear-localized member, suggesting a role in gene regulation.4 When BAP1 was first discovered as a BRCA1-interacting protein and later shown to bind to BARD1, the focus was on DNA repair and genomic instability. Although there is some evidence that BAP1 may play a role in BRCA1-mediated DNA repair pathways, that connection remains unresolved. The more established function for BAP1 is its role as a core catalytic component of human polycomb-like multiprotein complexes that regulate gene expression. This complex contains various proteins, including polycomb proteins ASXL1/2, YY1, and OGT. The core BAP1-ASXL1/2 complex interacts with host cell factor-1 (HCF-1) and histone-modifying complexes during cell division.16 Studies in which BAP1 cellular levels or enzymatic activity were altered experimentally have revealed defects in cell cycle progression at G1/S, and BAP1 is thought to influence cell proliferation by coregulating transcription from HCF-1/E2F-governed promoters.17 BAP1 has also been shown to interact with ASXL1/2 to form the polycomb group repressive deubiquitinase complex (PR-DUB), which is involved in stem cell pluripotency and development.18 Mutations of BAP1 and potentially genes encoding other PR-DUB components may alter the function of the holo-complex leading to tumorigenesis. Germane to this, somatic ASXL1/2 alterations have been detected in human myelodysplastic disorders and solid tumors, and a conditional, systemic knockout model in which Bap1 was homozygously deleted in adult mice recapitulated features of human myelodysplastic syndrome.19

Unresolved Questions and Conclusions

While the first two reports of germline inactivating BAP1 mutations focused on different disease entities—that is, one on families with a high incidence of MM,6 and the other on families with multiple melanocytic tumors7—both studies found recurrent UMs as well. As proposed by Goldstein,20 current evidence supports the notion that these initial reports of germline BAP1 mutations were describing a single syndrome consisting of a range of tumors with varying penetrance.

Although there is mounting evidence for the existence of a novel BAP1 cancer syndrome, many questions remain. For example, what is the gamut of tumor types connected with the disorder? It is clear that MM, UM, CM, and benign melanocytic skin lesions are part of the spectrum of tumors associated with the BAP1 syndrome; however, genetic epidemiologic studies will be required to determine if there is significant susceptibility to other tumor types (paraganglioma, RCC, lung, and breast carcinomas), each of which has been reported in some BAP1 carriers. Furthermore, why are two distinct tumor types—MM, derived from mesothelial lining, and atypical melanocytic tumors/UM/CM, derived from melanocytes—associated with this syndrome? Is tumor type specificity influenced by the subunit compositions of PR-DUB complexes in each precursor tissue? Similarly, the tumor spectrum connected with Li-Fraumeni syndrome extends from epithelial cancers to sarcomas to brain tumors. Moreover, why do BAP1 mutations predispose to cancer when present in the germ line, yet act as a late, somatic event in connection with UM metastasis? It is also unclear if variations in the number of melanocytic tumors and incidence of MM among BAP1 mutation carriers reflect differences in
genetic background of affected individuals or differences in exposure to carcinogens.

Collectively, these new findings will help to identify individuals at high risk of MM, CM, and potentially other cancers who could be targeted for early intervention. BAP1 mutation carriers should be regularly monitored for evidence of early malignancy, and preventive measures such as avoidance of exposure to asbestos and sun should be implemented.

**LI-FRAUMENI SYNDROME: GENETIC BASIS FOR CLINICAL SURVEILLANCE**

In 1969, Li and Fraumeni described four families in whom soft tissue sarcoma was associated with early-onset breast cancer in close female relatives. Since then, many families have been identified and not reported. The underlying cause of the majority of LFS cases is a germline TP53 mutation (Fig. 1). Mutant p53 loss-of-function, dominant-negative, and gain-of-function properties are all important for tumorigenesis in humans, with gain-of-function activities being particularly relevant. Currently, 80% of LFS families that fulfill the classical clinical criteria (Table 1) harbor TP53 germline mutations—most of which reside in the DBD. Causal mutations in genes other than TP53 have not been reproducibly observed, although it is anticipated the new platforms for whole genome and whole exome sequencing may uncover candidate genes.

LFS accounts for 17% of all genetically defined familial cancer cases. Over 500 families have been reported worldwide with complete or partial (LFS-like) phenotypes, and many more families have been identified and not reported. The TP53 carrier rate is about 1 in 5,000 births. LFS is a highly penetrant disorder with the lifetime risk of developing cancer being 93% in men and 68% in women. The gender difference cannot be explained by breast or sex-related cancers, since the difference remained after exclusion of breast, ovary and prostate cancer. Females also exhibit an earlier average age of onset (29 years vs. 40 years in men). The age distribution at cancer diagnosis is strikingly young, with up to 56% of diagnoses under 30 years of age and 78% under 50 years.

Specific TP53 mutant genotype may influence age of onset and tumor spectrum. Birch and colleagues reported a significantly higher incidence and earlier age at cancer diagnosis for breast (p = 0.006) and brain cancers (p = 0.05) in families who carry missense mutations in the DBD. Conversely, whereas families in whom ACCs occur together with a wider spectrum of cancers harbor the usual spectrum of germline mutations, those with isolated ACC or apparently de novo mutations are commonly found to occur outside the DNA-binding loops. Furthermore, nonsense, frameshift, and splice mutations are associated with particularly early tumor onset. However, these genotype:phenotype correlations are not consistent, as numerous families carrying the same mutation express widely divergent clinical manifestations of age of onset and cancer type.

The difficulty in clarifying an absolute clinical definition for LFS has likely led to under-reporting of cases. Various clinical definitions of LFS as well as incomplete phenotypes—LFS-like (LFL) and incomplete LFS (LFSI)—have been suggested in order to more accurately represent the TP53 genotype:phenotype correlation. Table 1 highlights the comparative phenotypic characteristics of the classical and related definitions of LFS. The sensitivity and specificity of the Chompret criteria are 82% and 58%, respectively, making it perhaps the most rigorous and relevant definition to justify TP53 mutation analysis. ACC represents 14% of all cancers in LFS and occurs primarily in children. Breast sarcomas occur mainly in young adolescents. Brain tumors and soft tissue sarcomas exhibit a biphasic age distribution, with a first peak in very early childhood (< 5 years) and a second peak between 20 and 40 years. Approximately 10% of patients with

<table>
<thead>
<tr>
<th>TABLE 1. Clinical Criteria for Classic LFS, LFS-like Criteria, and Chompret Criteria</th>
</tr>
</thead>
</table>
| **Classic LFS Criteria:**
| • Proband diagnosed with a sarcoma before age 45 |
| • A first-degree relative with cancer diagnosed before age 45 |
| • A first- or second-degree relative on the same side of the family with cancer diagnosed before age 45 or a sarcoma at any age |
| **LFS-like Criteria Birch:**
| • Proband with any childhood cancer or sarcoma, brain tumor, or adrenocortical carcinoma diagnosed before age 45 |
| • First- or second-degree relative with a typical LFS cancer (sarcoma, breast cancer, brain tumor, leukemia, or adrenocortical carcinoma) diagnosed at any age and |
| • A first- or second-degree relative on the same side of the family with any cancer diagnosed under age 60 |
| **Eeles definition of LFL:**
| • Two first- or second-degree relatives with LFS related malignancies at any age |
| **Chompret criteria for LFS:**
| • A proband diagnosed with a narrow-spectrum cancer (sarcoma, brain tumor, breast cancer, or adrenocortical carcinoma) before age 36 and at least one first- or second-degree relative |
| • A proband with multiple primary tumors, two of which belong to the narrow spectrum and the first of which occurred before age 36, regardless of family history |
| • A proband with adrenocortical carcinoma, regardless of age at diagnosis or family history |

Abbreviations: LFS, Li-Fraumeni syndrome; LFL, Li-Fraumeni-like.

* First-degree relative is defined as a parent, sibling, or child.
* Second-degree relative is defined as a grandparent, aunt, uncle, niece, nephew, or grandchild.
LFS develop gliomas, typically before the age of 45 years. Up to 5% of patients develop supratentorial primary neuroectodermal tumors, choroid plexus carcinoma (CPCs), and medulloblastomas. Almost 50% of children with CPC harbor germline TP53 mutations even in the absence of a typical LFS family history. Therefore, children with CPC or ACC should be considered for TP53 mutation analysis.

Approximately 20% to 30% of tumors in TP53 mutation carriers do not belong to the classical LFS tumor spectrum. Wilms tumor and phyllodes tumors of the breast are strongly associated, pancreatic cancer moderately associated, and neuroblastoma weakly associated with TP53 mutation carrier status. Carcinomas of the lung and gastrointestinal tract, lymphomas, and other neoplasms have been shown to occur in TP53 mutation carriers or first-degree relatives of carriers at much earlier ages than seen in the general population.

Approximately 1% of heritable breast cancers arise due to a germline TP53 mutation. However, 7% of women who develop breast cancer under 30 years of age and have no first- or second-degree relatives with cancer carry a TP53 mutation; presence of first- or second-degree relatives with cancer raises this likelihood to well over 75%. Occurrence of multiple metachronous or synchronous primary cancers is one of the remarkable phenotypes observed in LFS. Age and tumor diagnosis influence the risk of second malignant neoplasms (SMN), with the highest risk being in those who developed their first tumor in the first two decades of life or those diagnosed with rhabdomyosarcoma (RMS). In TP53 mutation carriers, the cumulative probability of a second cancer is 57% (±10%) at 30 years. The relative risk in individuals whose first cancer was diagnosed before age 20 is 83, (95% CI 37–187) decreasing to 9.7 (95% CI 4.9–20) for ages 20 to 44, and to 1.5 (95% CI 0.5–4.2) for age 45 and older at first cancer diagnosis.

A unique R337H mutation exclusively found in LFS families from southeastern Brazil is a risk allele for pediatric ACC and, until recently, was thought to represent a unique example of a tissue-specific predisposing mutation. The carrier frequency in southeastern Brazil is 0.3%. Nonbiased ascertainment of families with the R337H mutation shows that the cancer risk encompasses the full spectrum of tumors associated with LFS, in particular early-onset breast cancer (mean age at diagnosis below 40 years) and CPC. Additionally, current data on overall cancer penetrance suggest that the age-related cancer risk is somewhat lower than in LFS associated with other TP53 mutations, with tumors detected in approximately 25% of carriers at the age of 30 and a lifetime risk of approximately 80%.

Some TP53 polymorphisms do not appear to be phenotypically silent. The PIN3 (16 bp duplication in intron 3) polymorphism has been associated with an increase in age of onset of tumors in TP53 mutation carriers. A single nucleotide polymorphism (SNP) at codon 72 in exon 4 involves the substitution of an arginine for a proline base. The current consensus from a large number of studies is that R72 is more effective in inducing apoptosis than P72. The effect of this polymorphism in determining clinical phenotype or outcome is not known. On the other hand, the SNP309, rs2279744 T/G polymorphic substitution in the MDM2 gene appears to confer an earlier age of onset in LFS patients.

In LFS, decrease in age of cancer onset and increase in cancer incidence in successive generations have both been observed. Interestingly, telomeres in peripheral blood leukocytes of TP53 mutation carriers are shorter than in normal individuals of corresponding age. This difference was more pronounced in children (34% decrease) than in adults (19% decrease). The accelerated telomere attrition in TP53 mutation carriers is postulated to lead to greater genomic instability and earlier age of cancer onset in successive generations. Global copy number variation frequency and total structural variation are significantly increased in individuals with germline TP53 mutations (p = 0.01). In addition, among families with a history of cancer, offspring were significantly more likely to have an increase in CNVs when compared with their mutation carrier parent. These findings, together with the accelerated telomere attrition data, support the notion that TP53 mutation carriers have inherently unstable genomes and harbor other genetic and genomic alterations that can directly modify the age phenotype. Recent evidence suggests that the “early” germline presence of TP53 mutations in a cell may induce early critical telomere length shortening, which in turn may be involved in chromothripsis—an event of catastrophic chromosome rearrangement that is frequently seen in LFS-associated tumors. What the other genetic events are that modify the “driver” genotype conferred by the germline TP53 mutation are being actively explored and may ultimately lead to the development of more precise predictive algorithms of cancer phenotype and disease risk.

**Screening and Surveillance in LFS**
For both at-risk children and adults, lifestyle counseling to avoid ionizing radiation and other DNA-damaging agents is particularly relevant. For female TP53 mutation carriers, the role of prophylactic mastectomy has not been carefully evaluated. Prenatal or preimplantation genetic testing can be offered to fertile couples affected by LFS. Ultimately, determining the exact nature of the TP53 mutation may be of prognostic significance and therefore important for the clinical management of these patients. Most importantly, a high index of suspicion should be maintained for known LFS carriers who complain of persisting but unexplained symptoms.

The diversity of tumors occurring in LFS families has prompted investigators to evaluate the use of biochemical and imaging modalities to identify tumors. Although FDG-PET/CT can identify new primary cancers in TP53 mutation carriers, repeated radiation exposure may accelerate the risk of secondary malignancies. With this in mind, a recent study by Villani and colleagues suggests that an aggressive multimodality approach to clinical surveillance using a combination of biochemical markers of disease, abdominal-pelvic ultrasound, rapid-sequence whole-body MRI, and dedicated brain MRI in both children and adults...
does identify presymptomatic cancers. Colonoscopy and breast MRI are also included in the adult surveillance protocol. Many of the tumors detected are low-grade or low stage, and their early detection appears to be correlated with improved outcome when compared against TP53 mutation carriers who did not undergo surveillance.

Studies to improve the predictive value of genetic and genomic modifier effects on the mutant TP53-associated phenotype will inform development of more refined tumor screening protocols and lead to improved understanding of the biologic mechanisms of tumor formation in these patients.

**SDHx GENE MUTATIONS: A NEW CLINICAL SYNDROME**

Paragangliomas are benign tumors that often occur in the head and neck region, along the parasympathetic chain. Also called glomus tumors, paragangliomas can develop along the glomus jugulare, tympanicum, vagale, or caroticum. These paragangliomas that develop along the parasympathetic chain usually do not secrete catecholamines. Similar tumors also can develop along the sympathetic chain, often referred to as pheochromocytomas when they are located within the adrenal gland. These sympathetic tumors also can be extra-adrenal, occurring alongside the aortapulmonary vasculature, the organ of Zuckercandl, or even the bladder and vas deferens. Sympathetic paragangliomas and pheochromocytomas often secrete catecholamines, which can be useful for early tumor screening/detection. Paragangliomas and pheochromocytomas are quite rare in the general population, occurring at an estimated incidence of 1 in 30,000 to 1 in 1 million. However, in the presence of an underlying germ-line SDH mutation, the tumor rate may be extraordinarily high with a penetrance approaching 80%. Studies to improve the predictive value of genetic and genomic modifier effects on the mutant TP53-associated phenotype will inform development of more refined tumor screening protocols and lead to improved understanding of the biologic mechanisms of tumor formation in these patients.

Cluster 1 (Cluster 1A: SDHx, Cluster 1B: VHL), associated with pseudohypoxia and aberrant VEGF signaling, and Cluster 2 (RET/NF1/TMEM127/MAX), associated with aberrant kinase signaling pathways.

In the absence of SDHx mutations, paragangliomas (and sometimes pheochromocytomas) are benign and very slow growing tumors. Many head and neck surgeons choose simply to observe these tumors and remove them only if they start to grow and physically impinge on vital structures. However, when such tumors occur because of germline mutations in SDHx genes, paragangliomas and pheochromocytomas can transform to become highly aggressive and metastatic. Once metastatic, these tumors become very difficult to cure. A recent study from the National Institutes of Health demonstrated that nearly 30% of nonmetastatic paragangliomas and pheochromocytomas are due to germline SDHx mutations, and that 44% of adults and 81% of children with metastatic disease are due to germline SDHx mutations. In fact, this study did not test for all of the known SDHx genes, so the actual prevalence of germline SDHx mutations in this disease may be higher.

Patients with metastatic paraganglioma or pheochromocytoma should be considered for genetic referral to test for underlying germline mutations, including the known SDHx genes.

Each SDHx gene mutation leads to a slightly different disease phenotype and clinical presentation (see Table 2). Interestingly, PGL-1 disease related to germline SDHD mutations is inherited in a maternally imprinted fashion with only the children of fathers—but not mothers—developing disease. Nevertheless, mothers can still pass SDHD mutations to their children. This is also true for germline SDHAF2 mutations (PGL-2), which are also inherited as a maternally imprinted disease. Disease caused by germline SDHB mutations (PGL-4) seems to be the most common and malignant of the clinical phenotypes in “Familial Paraganglioma and Pheochromocytoma Syndrome.” Every germline SDHx mutation (except SDHAF2) has been associated with GISTs. The association of paragangliomas with GISTs in the same patient has been called Carney-Stratakis syndrome, and germline SDHx genes have been found to be mutated in these patients. Previsously, clinical testing for the specific inherited SDHx mutations was based on disease presentation. For instance, a patient with metastatic paraganglioma that secretes catecholamine would first be tested for SDHB mutations, whereas a young patient with just familial head and neck paragangliomas might first be screened for SDHD or SDHC mutations. However, as technology moves toward hereditary gene panel testing, it is likely that all of these genes will be tested simultaneously in the future.

**SDHB Immunohistochemistry**

In order to identify patients at risk for underlying germline SDHx mutations, it was observed several years ago that tumor tissues could be stained by immunohistochemistry (IHC) for the SDHB protein. Lack of SDHB staining indicates that the SDH protein complex is not intact, which could be due to a defect in any one of the SDHx genes. In one
prospective study, SDHB IHC for identification of SDH-related tumors had sensitivity of 100% (95% CI 87–100), and identification of non-SDH-related tumors had specificity of 84% (95% CI 60–97). It has been suggested that IHC for SDHB should be used on any paraganglioma or pheochromocytoma not meeting the clinical criteria for MEN2, NF1, or VHL disease. If SDHB staining is absent, then SDHx genetic testing can be considered. Clinical laboratories are now beginning to offer SDHB IHC testing, but its ultimate sensitivity and specificity still needs to be determined in larger prospective trials. Currently, SDHB IHC seems to be most useful in the research setting.

**Surveillance**

Like LFS, we have learned that scheduled surveillance can detect early tumors in patients with underlying germline SDHx mutations. This is important so that smaller, asymptomatic SDH-deficient tumors can be removed before they transform to malignant and metastatic disease. Although no formalized screening guidelines exist, many clinicians perform annual physical examinations, blood pressure checks (for hypertension due to increased catecholamines), and blood work for serum metabolites. Previously, urine catecholamines were examined from 24-hour urine specimens, but many have eliminated urine screening in favor of serum testing. This blood work often includes fractionated catecholamines (epinephrine, norepinephrine, dopamine), fractionated free metanephrines (metanephrines, normetanephrine), and chromogranin A, all of which can be secreted by SDH-related tumors, given their sympathetic and parasympathetic origins. Fractionated plasma metanephrines have been reported to be the most sensitive and specific serum test for detecting secreting paragangliomas and pheochromocytomas. Fractionated metanephrines are nearly always abnormal in individuals with a hereditary syndrome characterized by secreting tumors (elevated metanephrines for RET and NF1 mutations and elevated normetanephrines for SDHx and VHL mutations). Increased methoxytyramine, a metabolite of dopamine, may be helpful for predicting the likelihood of metastatic disease and for distinguishing SDH-related tumors from VHL-related tumors. However, testing of methoxytyramine remains difficult to obtain clinically.

Regular imaging has been demonstrated to be very effective for identifying SDH-related tumors, especially in the setting of negative biochemical results. Screening approaches have included CT scans, MRI scans, [18F]fluorodeoxyglucose PET scans, and [123I]-metaiodobenzylguanidine scintigraphy. At the University of Utah, a recent prospective observational study of whole body, rapid sequence MRI in SDHx mutation carriers demonstrated MRI sensitivity of 88% and specificity of 95% to detect new tumors compared to biochemical testing sensitivity of 38% and specificity of 95% (K. Jasperson, personal communication, submitted). The University of Utah now recommends whole body MRI (5-mm slices from skull base to pelvis) at least every two years for patients with underlying SDHx mutations, followed by PET scans for patients with abnormal MRI results.

**GISTs and Other SDH-Deficient Tumors**

As testing for SDHx mutations has become more widespread, we have learned more about the spectrum of other SDH-related tumors, including GISTs, renal tumors (RCC, oncocyto ma), papillary thyroid cancer, pituitary tumors, and even neuroblastoma. In fact, wild-type GISTs lacking somatic KIT or PDGFA mutations have been shown to be 100% SDH-deficient as measured by SDHB IHC. Although rare, NIH has established a Pediatric and Wildtype GIST Clinic and through this effort has helped to better clinically define these SDH-deficient GISTs, which are often multifocal at diagnosis, 75% female, and more indolent. These SDH-deficient GISTs are often epithelioid or have mixed histology, grow in the muscularis propria in a microplexiform pattern, and commonly show lymph node metastases. Many recent reports have demonstrated germline SDHA mutations

### TABLE 2. Germline SDHx Mutations and Their Clinical Associations

<table>
<thead>
<tr>
<th>SDHA</th>
<th>SDHB</th>
<th>SDHC</th>
<th>SDHD</th>
<th>SDHAF2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Presentation Type</strong></td>
<td>PGL-5</td>
<td>PGL-4</td>
<td>PGL-3</td>
<td>PGL-1</td>
</tr>
<tr>
<td><strong>Chromosome Location</strong></td>
<td>5p15</td>
<td>1p35-36.1</td>
<td>1q21</td>
<td>11q23</td>
</tr>
<tr>
<td><strong>Inheritance Pattern</strong></td>
<td>Autosomal dominant</td>
<td>Autosomal dominant</td>
<td>Autosomal dominant</td>
<td>Autosomal dominant, maternal imprinting</td>
</tr>
<tr>
<td><strong>Catecholamine Secreting</strong></td>
<td>Yes</td>
<td>Frequent</td>
<td>Occasionally</td>
<td>Occasionally</td>
</tr>
<tr>
<td><strong>Malignant/Metastatic</strong></td>
<td>Yes</td>
<td>Frequent</td>
<td>Unknown</td>
<td>Occasionally</td>
</tr>
<tr>
<td><strong>Head and Neck PGLs</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Frequent</td>
<td>Frequent</td>
</tr>
<tr>
<td><strong>PCC (Any Abdominal)</strong></td>
<td>Frequent</td>
<td>Yes</td>
<td>Occasionally</td>
<td>Occasionally</td>
</tr>
<tr>
<td><strong>Associated with GIST</strong></td>
<td>Frequent</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Associated with Thyroid Cancer</strong></td>
<td>Unknown</td>
<td>Yes</td>
<td>Yes</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>Associated with Renal Tumors</strong></td>
<td>Unknown</td>
<td>Yes</td>
<td>Yes</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>Associated with NBL</strong></td>
<td>Unknown</td>
<td>Yes</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Abbreviations: PGL, paraganglioma; PCC, pheochromocytoma; GIST, gastrointestinal stromal tumor; RCC, renal cell carcinoma; NBL, neuroblastoma.
associated with SDH-deficient (wild-type KIT/PDFRA) GISTs,79,80 which can be detected by SDHA IHC.81,83 Germ-line SDHx mutations still account for less than half of SDH-deficient GISTs, and the search for underlying SDH-related genes continues for the majority of patients with SDH-deficient GISTs. It is now recommended that patients with SDH-deficient GISTs be referred for genetic evaluation for underlying SDHx mutations. If germline SDHx mutations are identified in patients with GISTs, they should be considered for biochemical and imaging surveillance due to risk for other tumors.

The Future of SDH Tumor Syndrome

As familial tumors due to inherited SDHx mutations become better recognized, we will begin to learn more about the genetic, epigenetic, and metabolic alterations related to cancer risk. Modifying genes will be identified, along with potential targets for novel prevention and therapeutic strategies. With a large enough cohort of patients, early tumor screening approaches can be assessed for effectiveness and ability to improve outcome. As with other rare cancer syndromes, collaboration and consortiums will be key to advancing our understanding of and treatment for SDH-deficient tumors.

CONCLUSION

Although rare, hereditary cancer syndromes provide an unparalleled opportunity to study the origin of a variety of cancers. As described above, this knowledge can be used to better understand tumorigenesis and develop novel approaches to the treatment of patients with cancer. The recognition of hereditary cancer syndromes in families may lead to enrollment in early prevention and screening trials. When dealing with individuals with such high risk for tumor development, the most effective interventions have been the early identification and removal of tumors. As we learn more about the specific molecular pathways altered in these hereditary cancer syndromes, even more targeted approaches can be developed to benefit patients either with or without familial cancers.

ACKNOWLEDGEMENTS

Grant Support: J.R.T. supported by NCI grants CA148805 and CA-06927, a grant from the Mesothelioma Applied Research Foundation, an appropriation from the Commonwealth of Pennsylvania, and a gift from the Local #14 Mesothelioma Fund of the International Association of Heat and Frost Insulators & Allied Workers in memory of Hank Vaughan and Alice Haas. D.M. is funded in part through grants from the Canadian Cancer Society (#701377) and the Canadian Institutes for Health Research. J.D.S. is a Damon Runyon Clinical Investigator supported by the Damon Runyon Cancer Research Foundation (CI#56–11), Alex’s Lemonade Stand Foundation, CureSearch for Children’s Cancer, and by NCI grant CA161780–01A1.

Disclosures of Potential Conflicts of Interest

Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate family member, those marked “B” are held by the author and an immediate family member. Relationships marked “U” are uncompensated.


References


64. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266:45-63.


